$2.51 Billion is the total value of Cormorant Asset Management, LP's 67 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 40.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
TPTX | Sell | TURNING POINT THERAPEUTICS I | $211,577,000 | +58.9% | 3,396,650 | -4.1% | 8.44% | +4.2% |
RETA | Sell | REATA PHARMACEUTICALS INCcl a | $166,897,000 | +153.6% | 816,400 | -0.4% | 6.66% | +66.2% |
MRTX | Sell | MIRATI THERAPEUTICS INC | $165,249,000 | +32.6% | 1,282,392 | -19.9% | 6.59% | -13.1% |
BBIO | Sell | BRIDGEBIO PHARMA INC | $88,076,000 | +56.7% | 2,512,865 | -4.0% | 3.52% | +2.7% |
APLS | Sell | APELLIS PHARMACEUTICALS INC | $82,674,000 | +15.3% | 2,700,000 | -9.3% | 3.30% | -24.4% |
CRSP | Sell | CRISPR THERAPEUTICS AGnamen akt | $60,905,000 | +37.0% | 1,000,000 | -7.8% | 2.43% | -10.2% |
ASND | Sell | ASCENDIS PHARMA A Ssponsored adr | $55,648,000 | +23.4% | 400,000 | -14.6% | 2.22% | -19.1% |
BHVN | Sell | BIOHAVEN PHARMACTL HLDG CO L | $54,440,000 | +1.8% | 1,000,000 | -22.0% | 2.17% | -33.3% |
RCKT | Sell | ROCKET PHARMACEUTICALS INC | $41,816,000 | +69.0% | 1,837,269 | -13.5% | 1.67% | +10.8% |
TCDA | Sell | TRICIDA INC | $35,022,000 | +4.8% | 927,975 | -14.3% | 1.40% | -31.3% |
QTNT | Sell | QUOTIENT LTD | $33,285,000 | +17.6% | 3,500,000 | -3.9% | 1.33% | -22.9% |
QURE | Sell | UNIQURE NV | $28,664,000 | -19.1% | 400,000 | -55.6% | 1.14% | -46.9% |
ALLK | Sell | ALLAKOS INC | $28,608,000 | -18.1% | 300,000 | -32.4% | 1.14% | -46.3% |
EIDX | Sell | EIDOS THERAPEUTICS INC | $28,448,000 | +46.3% | 495,692 | -8.3% | 1.14% | -4.1% |
DCPH | Sell | DECIPHERA PHARMACEUTICALS IN | $28,008,000 | +4.7% | 450,000 | -42.9% | 1.12% | -31.4% |
AMRN | Sell | AMARIN CORP PLCspons adr new | $27,872,000 | +38.0% | 1,300,000 | -2.4% | 1.11% | -9.5% |
BPMC | Sell | BLUEPRINT MEDICINES CORP | $27,638,000 | -23.7% | 345,000 | -30.0% | 1.10% | -50.0% |
BHVN | Sell | BIOHAVEN PHARMACTL HLDG CO Lcall | $27,220,000 | +8.7% | 500,000 | -16.7% | 1.09% | -28.7% |
GLPG | Sell | GALAPAGOS NVspon adr | $20,921,000 | -8.5% | 100,000 | -33.3% | 0.84% | -40.0% |
ARGX | Sell | ARGENX SEsponsored adr | $16,052,000 | +10.0% | 100,000 | -21.9% | 0.64% | -27.9% |
KURA | Sell | KURA ONCOLOGY INC | $13,750,000 | -26.4% | 1,000,000 | -18.8% | 0.55% | -51.7% |
EIGR | Sell | EIGER BIOPHARMACEUTICALS INC | $12,418,000 | +21.4% | 833,400 | -16.5% | 0.50% | -20.4% |
DTIL | Sell | PRECISION BIOSCIENCES INC | $6,494,000 | +65.6% | 467,516 | -0.0% | 0.26% | +8.4% |
AVRO | Sell | AVROBIO INC | $6,393,000 | -20.3% | 317,579 | -44.1% | 0.26% | -47.7% |
ANAB | Sell | ANAPTYSBIO INC | $5,931,000 | -71.3% | 365,000 | -38.3% | 0.24% | -81.2% |
BCEL | Sell | ATRECA INC | $5,045,000 | +1.5% | 326,141 | -19.7% | 0.20% | -33.7% |
ORTX | Sell | ORCHARD THERAPEUTICS PLCads | $4,815,000 | -40.0% | 350,203 | -48.1% | 0.19% | -60.7% |
GOSS | Sell | GOSSAMER BIO INC | $4,689,000 | -54.8% | 300,000 | -51.5% | 0.19% | -70.4% |
NKTR | Sell | NEKTAR THERAPEUTICS | $4,317,000 | -70.0% | 200,000 | -74.6% | 0.17% | -80.3% |
XFOR | Sell | X4 PHARMACEUTICALS INC | $2,704,000 | -75.9% | 252,747 | -71.3% | 0.11% | -84.2% |
OTLK | Exit | OUTLOOK THERAPEUTICS INC | $0 | – | -15,753 | -100.0% | -0.00% | – |
ACRS | Exit | ACLARIS THERAPEUTICS INC | $0 | – | -250,000 | -100.0% | -0.02% | – |
ABEO | Exit | ABEONA THERAPEUTICS INC | $0 | – | -200,000 | -100.0% | -0.03% | – |
IFRX | Exit | INFLARX NV | $0 | – | -300,000 | -100.0% | -0.04% | – |
XLRN | Exit | ACCELERON PHARMA INC | $0 | – | -25,000 | -100.0% | -0.06% | – |
GTHX | Exit | G1 THERAPEUTICS INC | $0 | – | -1,000 | -100.0% | -0.06% | – |
SRRK | Exit | SCHOLAR ROCK HLDG CORP | $0 | – | -118,950 | -100.0% | -0.06% | – |
BOLD | Exit | AUDENTES THERAPEUTICS INC | $0 | – | -50,000 | -100.0% | -0.09% | – |
ADVM | Exit | ADVERUM BIOTECHNOLOGIES INCcall | $0 | – | -300,000 | -100.0% | -0.10% | – |
ITRM | Exit | ITERUM THERAPEUTICS PLC | $0 | – | -396,385 | -100.0% | -0.14% | – |
KZR | Exit | KEZAR LIFE SCIENCES INC | $0 | – | -927,869 | -100.0% | -0.18% | – |
PHAS | Exit | PHASEBIO PHARMACEUTICALS INC | $0 | – | -816,448 | -100.0% | -0.21% | – |
RUBY | Exit | RUBIUS THERAPEUTICS INC | $0 | – | -491,700 | -100.0% | -0.24% | – |
ATRA | Exit | ATARA BIOTHERAPEUTICS INC | $0 | – | -300,000 | -100.0% | -0.26% | – |
FIXX | Exit | HOMOLOGY MEDICINES INC | $0 | – | -245,100 | -100.0% | -0.27% | – |
GNFT | Exit | GENFIT S Aads | $0 | – | -300,000 | -100.0% | -0.32% | – |
HSACU | Exit | HEALTH SCIENCES ACQUISITN CORPunit 04/01/2024 | $0 | – | -1,080,000 | -100.0% | -0.70% | – |
SAGE | Exit | SAGE THERAPEUTICS INC | $0 | – | -88,700 | -100.0% | -0.76% | – |
MRTX | Exit | MIRATI THERAPEUTICS INCput | $0 | – | -550,000 | -100.0% | -2.61% | – |
SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -400,000 | -100.0% | -7.23% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
OMEROS CORP | 27 | Q3 2021 | 6.5% |
MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
SC 13G | 2024-05-13 |
4 | 2024-05-08 |
SC 13G | 2024-04-29 |
4 | 2024-04-22 |
SC 13G/A | 2024-04-15 |
4 | 2024-04-03 |
SC 13G | 2024-03-21 |
4 | 2024-03-18 |
SC 13G/A | 2024-03-18 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.